期刊文献+

英夫利西单抗治疗类风湿关节炎和强直性脊柱炎的参考意见 被引量:7

原文传递
导出
摘要 类风湿关节炎(RA)和强直性脊柱炎(AS)是一种病因%未完全阐明的炎性疾病,在其发病过程中,TNFα等炎性因产扮演了至关重要的角色。
作者
出处 《中华内科杂志》 CAS CSCD 北大核心 2012年第12期1011-1016,共6页 Chinese Journal of Internal Medicine
  • 相关文献

参考文献60

  • 1SmolenJ S, Aletaha D, BiJ lsmaJ W, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis,2010,69:631-637.
  • 2强直性脊柱炎诊断及治疗指南[J].中华风湿病学杂志,2010,14(8):557-559. 被引量:846
  • 3BraunJ , van den Berg R, Baraliakos X, et al. 20 10 update of the ASAS/EULAR recommendations forthe management of ankylosing spondylitis. Ann Rheum Dis,2011 ,70:896-904.
  • 4Aletaha D, Neogi T, Silman AJ , et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatologyl European League Against Rheumatism collaborative initiative. Arthritis Rheum, 20 10 ,62 : 2569-2581.
  • 5Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum,1988,31 :315-324.
  • 6类风湿关节炎诊断及治疗指南[J].中华风湿病学杂志,2010,14(4):265-270. 被引量:1276
  • 7SinghJ A, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) , 2012,64 :625-639.
  • 8Visser K, Goekoop-Ruiterman YP, de Vries-BouwstraJ K,et al. A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. Ann Rheum Dis,2010,69:1333-1337.
  • 9Furst DE, Keystone EC, BraunJ , et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis,2012,71 SuppI2:i245.
  • 10van der HeiJ de D, SieperJ , Maksymowych WP , et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis, 2011,70:905-908.

二级参考文献25

  • 1中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南[J].中华流行病学杂志,2006,27(1):79-88. 被引量:389
  • 2Wolfe F.Zwillich sH.The long-term outcomes of rheumatoid arthritis:a 23-year prospective,longitudinal study of total joint replacement and its predictors in 1600 patients with rheumatoid arthritis.Arthritis Rheum.1998,41:1072-1082.
  • 3Fehon DT,Anderson JJ.American College of ILheumatology preliminary definition of improvement in rheumatoid arthritis.Arthritis Rhearn,1995,38:727-735.
  • 4Fex E,Jomson K,Johnson U,et al.Development of radiographic damage during the flint 5-6 yr of rheumatoid arthritis:a prospective follow-up study of a Swedish cohort.Br J Rheumatol,1996.35:1106-1115.
  • 5Fuchs HA,Kaye JJ,Callahan LF,et al.Evidence of significant radiographic damagein rheumatoid arthritiswithinthefirst2 years ofdisease.J Rheumatol,1989,15:585-591.
  • 6Mǒttǒnen TT.Prediction of erosiveness and rate ofdevelopment of new erosions in early rheumatoid arthritis.Ann Rheum Dis,1988.47:648-653.
  • 7Brerman FM,Maini RN,Feldmann M.TNFα-a pivotal role in rheumatoid arthritis?Br J Rheumatul,1992,31:293-298.
  • 8Emery P,Breedveld FC,Hau S,et al.Comparison of methotrexate monotherapy with a eombination of methotrexate and etanercept in active.early.mederate to gevere rheumatoid arthritis(COMET):a randomised,double-blind,parallel treatment trial.Lancet,2008.372:375-382.
  • 9Weinblatt ME,Kremer JM,Bankhurst AD,et al.A trial of etaIlercept.a recombinant tumor necrosis factor receptor:Fc fusion protein,in patients with rheumatoid arthritis receiving methotrexato.N Engl J Med,1999,340:253-259.
  • 10Maini RN,St Clair EW,Breedveld F,et al.Randomised phase Ⅲtrial of infliximub combined with ongoing methotrmmte in the treatment of rheumatoid arthritis with persistent disease activity.Lancet,1999,354:1932-1939.

共引文献2114

同被引文献107

  • 1赵慧,汪静,杨喜云,郭建,王宏沛,沈海丽.英夫利昔单抗治疗强直性脊柱炎累及颞颌关节一例[J].中华临床医师杂志(电子版),2011,5(7):2162-2163. 被引量:1
  • 2张莉芸,黄烽.生物制剂治疗强直性脊柱炎研究进展[J].中华风湿病学杂志,2005,9(2):112-115. 被引量:50
  • 3Listing J,Brandt J,Rudwaleit M,et al.Impact of anti-tumour necrosis factor alpha treatment on admissions to hospital and days of sick leave in patients with ankylosingspondylitis[J].Ann Rheum Dis,2004,63(12):1670-1672.
  • 4Kobelt G,Andlin-Sobocki P,Brophy S,et al.The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab(Remicade)[J].Rheumatology(Oxford),2004,43(9):1158-1166.
  • 5Fautrel B,Benhamou M,Breban M,et al.Cost effectiveness of two therapeutic regimens of infliximab in ankylosing spondylitis:economic evaluation within a randomised controlled trial[J].Ann Rheum Dis,2010,69(2):424-427.
  • 6Brandt J, Haibel H, Comely D, et al.Successful treatment of active ankylosing spondylitis with the anti-tumor necro- sis factor-alpha monoclonal antibody infliximab[J]. Arthri- tis Rheum,2001,44(12) :2 936.
  • 7Braun J, Baraliakos X, Golder W, et al. Magnetic reso-naace imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful thera- py with infliximab: evaluation of a new scoring system[J]. Arthritis Rheum, 2003,48(4) : 1 126.
  • 8Theis VS, Rhodes JM. Review article: minimizing tubercu- losis during anti-tumor necrosis factor-alpha treatment of inflammatory bowel disease[J]. Aliment Pharmacol Ther, 2008,27(1) : 19.
  • 9Wolfe F, Michaud K, Anderson J, et al.Tuberculosis infec- tion in patients with rheumatoid arthritis and the effect of infliximab therapy[J]. Arthritis Rheum, 2004,50 (2) : 372.
  • 10Dixon WG , Hyrich KL , Watson KD, et al.BSRBR Con- trol Centre Consortium, and DPM Symmonsl, on behalf of the BSR biologics register drug-specific risk of tubercu- losis in patients with rheumatoid arthritis treated with an- ti-TNF therapy: results from the British Society for Rheu- matology Biologics Register (BSRBR)[J]. Ann Rheum Dis, 2010,69(3) : 522.

引证文献7

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部